Investigational drug · Phase 2
THDBH120
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight or Obese.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "THDBH120"
First trial start
2025
Jan 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "THDBH120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight or Obese
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "THDBH120" as an intervention, largest first.
- Phase II Study of THDBH120 Injection in Overweight or Obese SubjectsPivotal-lookingRecruiting
Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
NCT07036601 · 276 participants (planned) · Start Jan 6, 2025 · Primary completion Feb 13, 2026
Drug: THDBH120 injection; Placebo of THDBH120 injection · For: Overweight or Obese
Sites: Changsha, China
Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
NCT06744868 · 72 participants · Start Dec 19, 2023 · Primary completion Sep 22, 2024
Drug: THDBH120 injection (SAD); Placebo of THDBH120 injection (SAD) and 2 more · For: Healthy
Sites: Beijing, China
Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
NCT07020949 · 49 participants · Start Jun 13, 2024 · Primary completion Nov 27, 2024
Drug: THDBH120 injection; Placebo of THDBH120 injection · For: Diabetes Mellitus Type 2
Sites: Beijing, China
Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
NCT06951945 · 36 participants · Start Jul 18, 2024 · Primary completion Dec 23, 2024
Drug: THDBH120 injection; Placebo of THDBH120 injection · For: Obesity
Sites: Anhui, China; Zhejiang, China
Newest research
PubMed records naming it or its code names, newest first.
- A novel GIPR/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity.
Zhang F, Chen W, Wang H, et al. · J Adv Res 2026
Also in development for Overweight or Obese
- EnicepatideCT-388, RO7795068Phase 22 trials
Carmot Therapeutics, Inc. · Obesity, Overweight, Overweight or Obese
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.